Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
Compose a Response to This Article
Other responses
No responses have been published for this article.
